Catalyst Pharmaceuticals (CPRX) Reports Record Q4 and Full Year 2025 Results
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is one of the best cheap biotech stocks to buy now. Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals Inc. (CPRX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | HBK Investments David Costen Haley | 2,820,302 | $88,642,092 | 0.87% | |
| 2. | Renaissance Technologies Jim Simons | 2,136,077 | $67,136,900 | -10% | 0.09% |
| 3. | Highland Capital Management James Dondero | 1,602,557 | $50,368,367 | 3.37% | |
| 4. | Millennium Management Israel Englander | 1,068,724 | $33,589,995 | +40% | 0.01% |
| 5. | Water Island Capital John Orrico | 933,819 | $29,349,931 | 2.73% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.99 | 7,000 | $20,930.00 | 560,376 | 2020-09-30 | Filing | |
| $2.97 | 15,000 | $44,550.00 | 4,787,693 | 2020-09-30 | Filing | |
| $4.70 | 10,000 | $46,950.00 | 553,376 | 2019-10-11 | Filing | |
| $4.89 | 10,000 | $48,900.00 | 4,772,693 | 2019-10-03 | Filing | |
| $3.23 | 25,000 | $80,750.00 | 4,762,693 | 2019-06-11 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $23.06 | 6,746 | $155,562.76 | 2,360 | 2025-12-12 | Filing | |
| $23.73 | 4,473 | $106,162.18 | 9,106 | 2025-12-12 | Filing | |
| $23.20 | 15,527 | $360,195.35 | 13,579 | 2025-12-12 | Filing | |
| $23.33 | 10,983 | $256,244.37 | 3,962 | 2025-11-26 | Filing | |
| $22.70 | 40,000 | $908,000.00 | 231,039 | 2025-11-12 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 19,158,785 | $602,160,611 | 0.01% | |
| 2. | 7,627,036 | $239,718,530 | 0.01% | |
| 3. | 5,553,921 | $174,559,737 | 0.08% | |
| 4. | 5,135,345 | $161,403,893 | 0% | |
| 5. | 3,634,171 | $114,222,631 | 0.02% |
News See All
12 Cheap Biotech Stocks to Buy Now
On February 27, Eli Casdin, Casdin Capital CEO, appeared on CNBC’s ‘Closing Bell’ to talk about the biotech sector.
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q4 2025 Earnings Call Transcript
Operator: Good morning, and thank you for standing by. My name is John, and I will be your conference operator today.
Catalyst Pharmaceuticals, Inc. (CPRX): A Bull Case Theory
We came across a bullish thesis on Catalyst Pharmaceuticals, Inc. on BioEquity Watch’s Substack. In this article, we will summarize the bulls’ thesis on CPRX.
7 Stocks on Jim Cramer’s Radar Recently
“The market gets so angry over nothing. It's just plain irritable, very hard to please, like a 3-year-old child. But when you make it happy, the inner child giggles, and your stocks will soar.
Analysts See Big Upside in Catalyst Pharmaceuticals, Inc. (CPRX)
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is among the cheap healthcare stocks to buy heading into 2026. As of December 7, Catalyst Pharmaceuticals, Inc.
12 Cheap Healthcare Stocks to Buy Heading into 2026
Since the pandemic, healthcare is one of the sectors that have remained in the spotlight even amid market twists.
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q3 2025 Earnings Call Transcript
Operator: Greetings, and welcome to the Catalyst Pharmaceuticals Third Quarter 2025 Financial Results Conference Call and webcast. [Operator Instructions].
What do Analysts Think About Catalyst Pharmaceuticals (CPRX)?
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is one of the best biotech stocks with high potential. HC Wainwright reiterated a Buy rating on Catalyst Pharmaceuticals, Inc.
14 Biotech Stocks with High Potential
Healthcare was the second worst performer this year, with pharma and biotech companies under pressure.
Hedge Fund Resource Center